Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.

Detalles Bibliográficos
Publicado en:	European Radiology Vol. 33; no. 12; pp. 8669 - 8682
Autores principales:	Jin, Zhi-Cheng, Zhong, Bin-Yan, Chen, Jian-Jian, Zhu, Hai-Dong, Sun, Jun-Hui, Yin, Guo-Wen, Ge, Nai-Jian, Luo, Biao, Ding, Wen-Bin, Li, Wen-Hui, Chen, Li, Wang, Yu-Qing, Zhu, Xiao-Li, Yang, Wei-Zhu, Li, Hai-Liang, Teng, Gao-Jun
Formato:	Journal Article
Publicado:	Springer Nature Dec2023
Acceso en línea:	Ver este registro en EBSCOhost

Descripción
Descripción no disponible.